소아 성장호르몬결핍증 시장 - 세계 산업 규모, 점유율, 동향, 기회, 예측 : 유형별, 제품별, 용도별, 약물별, 유통 채널별, 지역별 및 경쟁(2021-2031년)

The Global Pediatric Growth Hormone Deficiency Market is projected to expand from USD 4.02 Billion in 2025 to USD 6.72 Billion by 2031, reflecting a CAGR of 8.94%. This market focuses on providing recombinant human growth hormone therapies to treat somatic growth failure in children resulting from insufficient endogenous hormone secretion. Key drivers propelling this trajectory include advancements in diagnostic tools that facilitate earlier disease detection and a rising global awareness regarding height-related developmental disorders. Additionally, supportive government reimbursement initiatives in developed nations help stabilize patient access to these vital biologic treatments, fostering steady demand independent of new formulation trends.

Despite these growth factors, the industry faces a substantial obstacle due to the shortage of specialized healthcare providers necessary to prescribe and monitor these complex therapies. According to the American Academy of Pediatrics, workforce density remained critically low in 2024, with approximately 2.0 pediatric endocrinologists for every 100,000 children in the United States. This scarcity of specialists creates significant bottlenecks in patient diagnosis and the initiation of treatment, thereby limiting the expansion of the addressable patient population and potentially impeding broader market penetration.

Market Driver

The commercialization of long-acting growth hormone formulations marks a significant evolution in the market, effectively resolving the historical issue of non-adherence linked to daily injection schedules. By lowering administration frequency to once-weekly doses, these advanced biologics notably enhance patient quality of life and treatment results, leading to rapid adoption within pediatric populations. The financial success of key innovators underscores the impact of this shift; for instance, Ascendis Pharma reported in their 'Third Quarter 2024 Financial Results' in November 2024 that revenue for Skytrofa, a long-acting lonapegsomatropin, hit €47.2 million, indicating a strong preference for these more convenient therapies. Concurrently, the rising prevalence of pediatric growth hormone deficiency combined with better diagnostic screening is widening the addressable patient base. Heightened awareness of height-related disorders is driving earlier intervention, a trend supported by the World Anti-Doping Agency's 'Physician Guidelines - Growth Hormone Deficiency' from May 2024, which estimates the condition's prevalence between 1:4000 and 1:10,000 children. Consequently, major pharmaceutical companies are seeing robust growth; Novo Nordisk's 'Annual Report 2024' highlighted a 31% increase in sales within their rare endocrine disorders division in 2024, largely fueled by the sustained global demand for these essential treatments.

Market Challenge

A primary structural barrier hindering the Global Pediatric Growth Hormone Deficiency Market is the shortage of specialized healthcare providers, specifically pediatric endocrinologists. Because these biological therapies necessitate precise dosage titration, strict safety monitoring, and ongoing management by certified specialists, the market's potential volume is capped by the limited capacity of the authorized workforce rather than solely by disease prevalence. When the supply of specialists cannot meet patient demand, it results in diagnostic bottlenecks and extended wait times, potentially causing patients to miss the critical biological windows necessary for effective growth hormone intervention. This challenge is exacerbated by a failure to replenish the specialist pipeline, posing a threat to future market penetration. As reported by the American Academy of Pediatrics in 2025, the pediatric endocrinology fellowship fill rate stood at only 48.1%, leaving over half of the training positions vacant. This significant shortfall in new entrants suggests that the prescriber shortage will intensify, further restricting patient access and limiting revenue scalability despite increasing disease awareness.

Market Trends

The incorporation of connected smart devices for adherence monitoring is transforming patient management by creating a direct digital link between families and healthcare providers. Bluetooth-enabled auto-injectors now transmit dosing data in real-time, enabling clinicians to address compliance issues immediately rather than waiting for scheduled visits. This connectivity notably enhances therapeutic results; according to 'Endocrine Abstracts' in May 2025, in a study on the impact of digital health platforms, patients managed by clinics with active digital engagement attained an optimal adherence rate of 88%. By enabling remote oversight, these technologies reduce the risk of growth failure due to missed doses. Simultaneously, the application of Artificial Intelligence is steering the market toward precision medicine through predictive treatment modeling. Machine learning algorithms are analyzing clinical variables to forecast individual growth responses, reducing the industry's reliance on trial-and-error dosing. As highlighted by 'Korea Biomedical Review' in May 2025, LG Chem's new AI model predicted child growth hormone responses with 98% accuracy, allowing endocrinologists to tailor therapies specifically to patients most likely to benefit.

Key Market Players

• Novo Nordisk A/S
• Eli Lily and Company
• Novartis AG
• Merck KgaA
• Pfizer Inc.
• Ferring B.V
• Genentech Inc
• BioParteners GmbH
• LG Chem Ltd.
• Ipsen S.A.

Report Scope

In this report, the Global Pediatric Growth Hormone Deficiency Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Pediatric Growth Hormone Deficiency Market, By Type

• Congenital GH Deficiency
• Acquired GH Deficiency
• Idiopathic GH Deficiency

Pediatric Growth Hormone Deficiency Market, By Product

• Powder
• Solvent

Pediatric Growth Hormone Deficiency Market, By Application

• Growth Hormone Deficiency
• Idiopathic Short Stature
• Turner Syndrome
• Small For Gestational Age
• Prader-Willi Syndrome
• Others

Pediatric Growth Hormone Deficiency Market, By Drug

• Genotropin
• Humatrope
• Norditropin Flexpro
• Others

Pediatric Growth Hormone Deficiency Market, By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others

Pediatric Growth Hormone Deficiency Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Pediatric Growth Hormone Deficiency Market.

Available Customizations:

Global Pediatric Growth Hormone Deficiency Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Pediatric Growth Hormone Deficiency Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Congenital GH Deficiency, Acquired GH Deficiency, Idiopathic GH Deficiency)
  • 5.2.2. By Product (Powder, Solvent)
  • 5.2.3. By Application (Growth Hormone Deficiency, Idiopathic Short Stature, Turner Syndrome, Small For Gestational Age, Prader-Willi Syndrome, Others)
  • 5.2.4. By Drug (Genotropin, Humatrope, Norditropin Flexpro, Others)
  • 5.2.5. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others)
  • 5.2.6. By Region
  • 5.2.7. By Company (2025)
• 5.3. Market Map

6. North America Pediatric Growth Hormone Deficiency Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Product
  • 6.2.3. By Application
  • 6.2.4. By Drug
  • 6.2.5. By Distribution Channel
  • 6.2.6. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Pediatric Growth Hormone Deficiency Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Product
      • 6.3.1.2.3. By Application
      • 6.3.1.2.4. By Drug
      • 6.3.1.2.5. By Distribution Channel
  • 6.3.2. Canada Pediatric Growth Hormone Deficiency Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Product
      • 6.3.2.2.3. By Application
      • 6.3.2.2.4. By Drug
      • 6.3.2.2.5. By Distribution Channel
  • 6.3.3. Mexico Pediatric Growth Hormone Deficiency Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Product
      • 6.3.3.2.3. By Application
      • 6.3.3.2.4. By Drug
      • 6.3.3.2.5. By Distribution Channel

7. Europe Pediatric Growth Hormone Deficiency Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Product
  • 7.2.3. By Application
  • 7.2.4. By Drug
  • 7.2.5. By Distribution Channel
  • 7.2.6. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Pediatric Growth Hormone Deficiency Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Product
      • 7.3.1.2.3. By Application
      • 7.3.1.2.4. By Drug
      • 7.3.1.2.5. By Distribution Channel
  • 7.3.2. France Pediatric Growth Hormone Deficiency Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Product
      • 7.3.2.2.3. By Application
      • 7.3.2.2.4. By Drug
      • 7.3.2.2.5. By Distribution Channel
  • 7.3.3. United Kingdom Pediatric Growth Hormone Deficiency Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Product
      • 7.3.3.2.3. By Application
      • 7.3.3.2.4. By Drug
      • 7.3.3.2.5. By Distribution Channel
  • 7.3.4. Italy Pediatric Growth Hormone Deficiency Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Product
      • 7.3.4.2.3. By Application
      • 7.3.4.2.4. By Drug
      • 7.3.4.2.5. By Distribution Channel
  • 7.3.5. Spain Pediatric Growth Hormone Deficiency Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Product
      • 7.3.5.2.3. By Application
      • 7.3.5.2.4. By Drug
      • 7.3.5.2.5. By Distribution Channel

8. Asia Pacific Pediatric Growth Hormone Deficiency Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Product
  • 8.2.3. By Application
  • 8.2.4. By Drug
  • 8.2.5. By Distribution Channel
  • 8.2.6. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Pediatric Growth Hormone Deficiency Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Product
      • 8.3.1.2.3. By Application
      • 8.3.1.2.4. By Drug
      • 8.3.1.2.5. By Distribution Channel
  • 8.3.2. India Pediatric Growth Hormone Deficiency Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Product
      • 8.3.2.2.3. By Application
      • 8.3.2.2.4. By Drug
      • 8.3.2.2.5. By Distribution Channel
  • 8.3.3. Japan Pediatric Growth Hormone Deficiency Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Product
      • 8.3.3.2.3. By Application
      • 8.3.3.2.4. By Drug
      • 8.3.3.2.5. By Distribution Channel
  • 8.3.4. South Korea Pediatric Growth Hormone Deficiency Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Product
      • 8.3.4.2.3. By Application
      • 8.3.4.2.4. By Drug
      • 8.3.4.2.5. By Distribution Channel
  • 8.3.5. Australia Pediatric Growth Hormone Deficiency Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Product
      • 8.3.5.2.3. By Application
      • 8.3.5.2.4. By Drug
      • 8.3.5.2.5. By Distribution Channel

9. Middle East & Africa Pediatric Growth Hormone Deficiency Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Product
  • 9.2.3. By Application
  • 9.2.4. By Drug
  • 9.2.5. By Distribution Channel
  • 9.2.6. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Pediatric Growth Hormone Deficiency Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Product
      • 9.3.1.2.3. By Application
      • 9.3.1.2.4. By Drug
      • 9.3.1.2.5. By Distribution Channel
  • 9.3.2. UAE Pediatric Growth Hormone Deficiency Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Product
      • 9.3.2.2.3. By Application
      • 9.3.2.2.4. By Drug
      • 9.3.2.2.5. By Distribution Channel
  • 9.3.3. South Africa Pediatric Growth Hormone Deficiency Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Product
      • 9.3.3.2.3. By Application
      • 9.3.3.2.4. By Drug
      • 9.3.3.2.5. By Distribution Channel

10. South America Pediatric Growth Hormone Deficiency Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Product
  • 10.2.3. By Application
  • 10.2.4. By Drug
  • 10.2.5. By Distribution Channel
  • 10.2.6. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Pediatric Growth Hormone Deficiency Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Product
      • 10.3.1.2.3. By Application
      • 10.3.1.2.4. By Drug
      • 10.3.1.2.5. By Distribution Channel
  • 10.3.2. Colombia Pediatric Growth Hormone Deficiency Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Product
      • 10.3.2.2.3. By Application
      • 10.3.2.2.4. By Drug
      • 10.3.2.2.5. By Distribution Channel
  • 10.3.3. Argentina Pediatric Growth Hormone Deficiency Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Product
      • 10.3.3.2.3. By Application
      • 10.3.3.2.4. By Drug
      • 10.3.3.2.5. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Pediatric Growth Hormone Deficiency Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Novo Nordisk A/S
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Eli Lily and Company
• 15.3. Novartis AG
• 15.4. Merck KgaA
• 15.5. Pfizer Inc.
• 15.6. Ferring B.V
• 15.7. Genentech Inc
• 15.8. BioParteners GmbH
• 15.9. LG Chem Ltd.
• 15.10. Ipsen S.A.

16. Strategic Recommendations

17. About Us & Disclaimer